TP53 and acute myeloid leukemia: Flotetuzumab, a CD123 x CD3 bispecific dual-affinity retargeting antibody (DART) molecule, demonstrated a promising efficacy in relapsed/refractory TP53-mutated AML, showing a 47% complete remission rate and a 10.3-month OS [60].